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Breast cancer is the most diagnosed malignancy in women, with over half
a million women dying from this disease each year. In our previous studies,
Δ40p53, an N-terminally truncated p53 isoform, was found to be upregu-
lated in breast cancers, and a high Δ40p53 : p53a ratio was linked with
worse disease-free survival. Although p53a inhibits cancer migration and
invasion, little is known about the role of Δ40p53 in regulating these
metastasis-related processes and its role in contributing to worse prognosis.
The aim of this study was to assess the role of Δ40p53 in breast cancer
migration and invasion. A relationship between D40p53 and gene expres-
sion profiles was identified in oestrogen-receptor-positive breast cancer
specimens. To further evaluate the role of D40p53 in oestrogen-receptor-
positive breast cancer, MCF-7 and ZR75-1 cell lines were transduced to
knockdown p53a or D40p53 and overexpress D40p53. Proliferation, migra-
tion and invasion were assessed in the transduced sublines, and gene
expression was assessed through RNA-sequencing and validated by
reverse-transcription quantitative PCR. Knockdown of both p53a and
Δ40p53 resulted in increased proliferation, whereas overexpression of
Δ40p53 reduced proliferation rates. p53a knockdown was also associated
with increased cell mobility. Δ40p53 overexpression reduced both migratory
and invasive properties of the transduced cells. Phenotypic findings are
supported by gene expression data, including differential expression of
LRG1, HYOU1, UBE2QL1, SERPINA5 and PCDH7. Taken together,
these results suggest that, at the basal level, Δ40p53 works similarly to
p53a in suppressing cellular mobility and proliferation, although the role
of D40p53 may be cell context-specific.
Abbreviations
B2M, b-microglobulin; DBD, DNA-binding domain; DEG, differentially expressed genes; ER+, oestrogen-receptor-positive; FDR, false
discovery rate; FFPE, formalin-fixed paraffin-embedded; FGFR3, fibroblast growth factor receptor 3; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; GSEA, gene set enrichment analysis; HDM2, human double minute-2; IDCs, invasive ductal carcinomas; IGF-1R, insulin
growth factor 1 receptor; miRNA, microRNA; MMPs, matrix metalloproteinases; OD, oligomerisation domain; p53RE, p53 response
element; RMA, robust multi-array analysis; SD, standard deviation; shNT, nontargeting shRNA-transduced cells serving as control; shRNA,
short-hairpin RNA; TAD, transactivation domain; wtp53a, wild-type full-length p53.
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1. Introduction
Breast cancer is the most commonly diagnosed malig-
nancy in females and accounts for over half a million
deaths in women worldwide [1]. TP53 is the most fre-
quently mutated gene in cancer. Wild-type p53 sup-
presses tumorigenesis through multiple pathways, such
as inducing cell-cycle arrest, apoptosis, senescence and
directly responding to oncogenic stress, whereas
mutant p53 can gain dominant negative functions,
contributing to tumorigenesis [2]. Intriguingly, p53
mutations are not ubiquitous in breast cancers (less
than 25% of all cases) [3], indicating that other mecha-
nisms are involved in ablating the canonical function
of p53.
In 2005, it was discovered that p53 can be expressed
as distinct protein isoforms other than the wild-type
full-length p53 (wtp53a) [4]. Truncation can occur at
the N terminus (D40p53, D133p53 and D160p53) or C
terminus (a, b and c) or both, giving rise to twelve iso-
forms retaining different proportions of the three main
functional domains: transactivation domain (including
TADI and II), DNA-binding domain (DBD) and
oligomerisation domain (OD) [4–6]. These domains are
critical for p53a to function. The regulatory function
of the truncated isoforms is not limited to their inter-
action with p53a [7]; D40p53a [8] and D133p53a [9]
can function independently of p53a.
D40p53a (Δ40p53 from here on) lacks the first 40
amino acids of p53a and can arise via two mecha-
nisms. It has been reported by us and others that
Δ40p53 is primarily generated by alternative splicing,
which retains intron 2 encompassing several stop
codons, thereby preventing p53a translation [10,11].
D40p53 can also be produced by alternative translation
at AUG40 [5]. The missing region encodes for TADI,
resulting in immunity to human double minute-2
(HDM2)-mediated degradation and partial loss of
transactivation ability [12]. The function of D40p53 is
difficult to interpret, and different roles have been
reported so far (for review, [13]).
Early studies showed that D40p53 heterotetramerisa-
tion led to elevated nuclear export of p53a, a reduc-
tion in the transactivation of certain p53a target genes
and inhibition of p53a-mediated apoptosis [5]. Hafsi
et al. co-transfected p53-null cell lines with expression
vectors for D40p53 and p53a at different amounts and
measured the transactivation activity of a reporter
gene containing the p53a response element of HDM2.
They found that if D40p53 was expressed at levels
higher than p53a (≥ 3 fold), D40p53 could inhibit
p53a’s function, whereas lower or equivalent levels of
D40p53 compared to p53a, had diverse effects that
were cell line specific [12]. It is deducible that high
levels of D40p53 compete with p53a in tetramer forma-
tion, and therefore, the canonical p53a function was
compromised.
Other studies showed that overexpression of D40p53
induced apoptosis in melanoma cell lines [14] and
reduced proliferation regardless of p53a status in hepa-
tocellular carcinoma cell lines [15], where D40p53 stim-
ulated the canonical function of p53a. Bourougaa
et al. (2010) reported that D40p53 induced G2 arrest,
while p53a induced G1 arrest, further establishing an
independent role for D40p53 [16]. Using point muta-
tions to inactivate phosphorylation residues, it was
shown that TADI and TADII induce the expression of
distinct genes, and hence, it is likely that the subset of
genes transactivated by D40p53, which lacks TADI, is
distinct from that of p53a [17]. Additionally, D40p53
has been shown to play a role in development. In
mice, overexpression of D40p53 led to the activation
of insulin growth factor 1 receptor (IGF-1R), main-
tainence of proliferation and self-renewal potential in
embryonic stem cells during early development [18].
D40p53 is overexpressed in multiple cancers such as
melanoma and breast cancer, and its expression has
been correlated with prognostic and therapeutic out-
comes [19,20], suggesting a role for D40p53 in disease
progression. Our group demonstrated the importance
of D40p53 expression in breast cancer. It is the most
highly expressed p53 isoform in breast cancer at the
mRNA level, and it is significantly upregulated in
tumours and cell lines compared to the normal breast.
A high D40p53 : p53a ratio (> 0.7) is significantly
associated with worse disease-free survival (HR 2.713)
[19]. These studies suggest that D40p53 may be
involved in cellular functions that promote the aggres-
siveness of breast cancer, but functional studies
demonstrating this are lacking, particularly on the
endogenously expressed isoform.
As a tumour suppressor, p53a regulates the expres-
sion of a plethora of genes and microRNAs linked to
the inhibition of proliferation, migration and invasion.
For instance, p53a is known to regulate the expression
of cell cycle regulatory genes CDKN1A and RB1,
growth factor receptors EGFR and MET, and matrix
metalloproteinases MMP2 and MMP9 [21], highlight-
ing p53a’s regulatory role in proliferation and migra-
tion. P53a also induces the expression of miR-34,
which anatagonises NOTCH, ZEB1 and SNAI1, fur-
ther exemplifying how p53a promotes cell adhesion
and reduces proliferation [22]. At the functional level,
p53a’s role in repressing migration and invasion has
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also been shown [23]. Hence, there is a growing body
of evidence suggesting a role for p53a in metastasis-
related processes; however, the role of Δ40p53 in this
context has not been examined. In this study, we
examined the role of D40p53 in migration, invasion
and in the regulation of gene expression to determine
whether this could provide an explanation for the
association of high D40p53 : p53a with worse survival
outcomes in breast cancer as identified in our previous
study [19]. Our results showed that molecular inhibi-
tion of p53a was associated with increased cell mobil-
ity, confirming the previous association of loss of p53a
function and increased metastatic potential. Overex-
pression of Δ40p53 reduced both migratory and inva-
sive properties of the transduced cells. Inhibition of
both p53a and Δ40p53 resulted in increased prolifera-
tion, while overexpression of Δ40p53 reduced prolifer-
ation rates. These phenotypic findings are supported
by gene expression data. Taken together, these results
suggest that at the basal level Δ40p53 works similarly
to p53a in suppressing cellular mobility and prolifera-
tion.
2. Materials and methods
2.1. Breast cancer samples
Breast cancer samples were acquired from the Aus-
tralian Breast Cancer Tissue Bank and have previously
been described [19,24]. All patients whose tissue sam-
ples were used in this study had an understanding of
and provided written consent for the use of their tissue
in research. mRNA that had been previously extracted
from these samples was used in our studies. The study
methodologies conformed to the standards set by the
Declaration of Helsinki and were approved by the
Hunter New England Human Research Ethics Com-
mittee (Approval number: 09/05/20/5.02).
2.2. RNA extraction
Total RNA was extracted from cells and formalin-
fixed paraffin-embedded (FFPE) tissues using Trizol
(Life Technologies, 15596026, Carlsbad, CA, USA).
2.3. Semiquantitative Real-time RT-PCR
cDNA was synthesised from 500 ng of total RNA using
the High-Capacity Reverse Transcription kit with
RNase Inhibitor (Life Technologies, N8080119). Semi-
quantitative PCR was performed using Universal Taq-
Man Master Mix or Universal TaqMan Advanced
Master Mix (RNA-seq validation only) (Life Technolo-
gies, 4364340 and 4444965) on an ABI 7500 cycler or a
Quant Studio 7 Pro PCR cycler (RNA-seq validation
only) with TaqMan gene expression assays (Life Tech-
nologies, 4331182): D40p53 [as previously described
[19]] and TP53 (Hs01034249_m1). Relative expression
was determined using the 2DDCt method [25] by nor-
malising to the housekeeping gene b-microglobulin
(B2M) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as previously described [19]. Additionally,
the expression of five differentially expressed genes iden-
tified by RNA-seq (based on mean normalised counts
and relevance) was confirmed by RT-qPCR using the
following probes: LRG1 (Hs00364835_m1), HYOU1
(Hs00197328_m1), UBE2QL1 (Hs00331876_m1);
SERPINA5 (Hs04333915_m1) and PCDH7
(Hs05574398_g1).
2.4. Human gene 1.0 array
100 ng of total RNA from FFPE samples was ampli-
fied (Ovation FFPE WTA kit) and biotinylated
(Encore Biotin module) according to the manufactur-
ers’ instructions (Nugen, San Carlos, CA, USA). The
arrays were scanned on an Affymetrix GeneChip Scan-
ner 3000 7G (Affymetrix, Santa Clara, CA, USA), the
data were imported to Genomic Suite 6.6 (Partek, St.
Louis, MO, USA), and a robust multi-array analysis
(RMA) was performed, which included log2 transfor-
mation, background correction, quantile normalisation
and summarisation of the probe features resulting in a
set of expression signal intensities. Unsupervised hier-
archical clustering was performed on genes that were
found to be differentially expressed in invasive ductal
carcinomas (IDCs) with high Δ40p53 compared to
IDCs with low Δ40p53 (P < 0.5; fold change > |1.5|).
Correction for multiple testing was performed using
the Benjamini–Hochberg procedure.
2.5. Cell culture
The human breast cancer cell lines MCF-7 and ZR75-
1 (with wtp53a) were kind gifts from Professor Chris-
tine Clarke (Westmead Millennium Institute, Univer-
sity of Sydney, Australia) and Dr Judith Weidenhofer
(The University of Newcastle, Australia), respectively.
Before the beginning of the experiments, the cell lines
were authenticated by the Australian Genome
Research Facility (Fine Mapping and Custom Geno-
typing, 6173, 100% for MCF-7 and 84.62% for ZR75-
1). Briefly, 1 9 106 cells were collected and DNA was
extracted by using Promega Genomic DNA purifica-
tion Kit (Promega, A1120, Madison, WI, USA).
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GenePrint 10 system (Promega, B9510) was used to
amplify 9 human loci from the extracted DNA and the
amplified PCR products were used to generate a
genetic profile, which was then compared to the profile
provided by the supplier of the cell line. Cells were
routinely cultured and passaged (up to the 20th pas-
sage after thawing) using DMEM [Life Technologies,
21063029), with 10% fetal bovine serum (FBS, Sigma-
Aldrich, F9423, St. Louis, MO, USA)], 200 mM L-
glutamine (Life Technologies, 25030081) and
2 µgmL1 insulin (Sigma-Aldrich, 19278). Cells were
kept in a cell culture incubator at 37 °C with 5% CO2
and humidity and routinely tested for mycoplasma
according to the manufacture’s recommendations
(MycoAlert PLUS, Lonza, LT07-701).
2.6. shRNA transduction
Short-hairpin RNAs (shRNAs) were designed to target
D40p53a/b/c isoforms (5’ AGACCTGTGGGAAGC-
GAAA 3’) or all other p53 isoforms (5’ GAAAC-
TACTTCCTGAAAAC 3’) and cloned into pLKO.1-
puro-CMV-tGFP vectors (MISSION Lentiviral
Transduction Particles, Sigma-Aldrich) to generate
specific and stable isoform knockdown in two
oestrogen-receptor-positive breast cancer cell lines,
MCF-7 and ZR75-1, expressing p53a. Our previous
study has shown other than p53a and D40p53a, the
mRNA expression levels of other p53 isoforms was
extremely low (almost undetectable) in breast cancer cell
lines [19,20,26], therefore, the shRNA-mediated knock-
down will primarily affect p53a and D40p53a expres-
sion, which will be referred to as shD40p53 and shp53a
for simplicity. Cells were cultured with optimised con-
centrations of transducing particle units and 8 lgmL1
hexadimethrine bromide (Sigma-Aldrich, H9268) for 24
to 48 h before changing to 1 lgmL1 puromycin-
supplemented media (puro-media, puromycin from
Sigma-Aldrich, P9620) to select transduced cells. Cells
were passaged in puro-media for three more passages,
until > 80% cells were GFP positive, prior to further
validation. Transduced sublines were maintained in
puro-media. Using this method Δ40p53 knockdown
sublines (-shΔ40p53), p53a knockdown sublines (-
shp53a) and nontargeting control sublines (-shNT) were
established in both MCF-7 and ZR75-1 cell lines.
2.7. Vector transductions
D40p53-overexpressing MCF-7 cells were created by
transducing MCF-7 cells with a lentiviral expression
construct containing D40p53. To generate the lentiviral
construct, the empty vector LeGO-iG2-puro+ was
linearised by digestion with BamH1 and Sbf1. D40p53
cDNA was amplified by PCR using primers, which
incorporated 14 bps of sequence homologous to the
LeGO-iG2-puro+ vector. The insert was then incorpo-
rated into the LeGO-iG2-puro+ vector by recombina-
tion (In-Fusion, Clontech). The D40p53 lentivirus was
then produced in 293T cells and used to transduce
MCF-7 cells. The resulting MCF-7 cells were main-
tained in puro-media as described above. Cells with
stable D40p53-overexpression are referred as MCF-7-
D40p53 and MCF-7-LeGO (empty vector control).
2.8. Western blot
Western blot analysis was carried out as previously
described [19,20,26]. A total of 30-50 µg of protein
extracts, obtained using 1% NP-40 lysis buffer [50 mM
Tris/HCl, 150 mM NaCl, 1% NP-40, pH 8.0, 19 Mini
Complete Protease Inhibitor EDTA-free cocktail tablets
(Roche Diagnostics, 11836153001)], were resolved on 8–
12% SDS/PAGE gels and transferred onto nitrocellulose
membranes. The membranes were blocked in Inter-
ceptTM PBS Blocking Buffer (LI-COR Biosciences, 927-
70001, Lincoln, NE, USA) and probed using primary
antibody anti-p53 (pantropic), clone DO-1 (Merck Milli-
pore, MABE327, Burlington, MA, USA) at a concentra-
tion of 1 µgmL1 (detects p53a, b and c) and KJCA40
(provided by Dr Jean-Christophe Bourdon) at a concen-
tration of 2.5 µgmL1 (detects all D40p53 variants).
GAPDH was used as a loading control (anti-rabbit:
Abcam, ab128915; anti-mouse: Calbiochem, CB1001).
Corresponding fluorescent secondary antibodies were
purchased from LI-COR Biosciences (Lincoln, 926-
32210 and 926-68023). Blots were visualised and quanti-
tated using the Odyssey CLx fluorescent imager (LI-
COR Biosciences, Lincoln, NE, USA) and Image Studio
Lite v4.0 (LI-COR Biosciences, Lincoln, NE, USA).
2.9. Proliferation assay
All MCF-7 sublines were plated into 96-well plates at
a seeding density of 3000 cellswell1 and monitored
using the IncuCyteTM ZOOM (Essen Bioscience, Ann
Arbor, MI, USA). Confluence was calculated with
integrated algorithms. All ZR75-1 sublines were plated
at a seeding density of 1 9 104 cellswell1 into four
individual 96-well plates to be processed every 24 h
until 96 h. Cell Titer Glo 2.0 reagent (Promega,
G9241) was applied to each plate according to the
manufacturer’s instructions and luminescence was
measured using a Cytation 3 (BioTek, Winooski, VT,
USA). All experiments were repeated three times on
separate days with three technical replicates.
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2.10. Migration/Invasion assay based on the
wound healing method
Migration and invasion were measured with the
wound healing assay as previously described [27].
Briefly, a coated (100 lLmL1 matrigel, Sigma-
Aldrich, E6909) 96-well plate (invasion assay) or an
uncoated 96-well plate (migration assay) was seeded
with cells overnight to achieve a confluent cell mono-
layer for the next day prior to the scratch. Plates for
the migration/invasion assay were scratched using the
96-well WoundMakerTM (Essen Bioscience). Dislodged
cell sheets were washed away with prewarmed media
and fresh media was added (migration assay). For the
invasion assay, matrigel was diluted to 125 lgmL1
with cold fresh media as previously described [28] and
50 lL was added to wells before gelation. Wounded
cells were placed into the IncuCyte (Essen Bioscience)
and monitored until the wounds closed.
2.11. Transwell migration assay
All cell lines were cultured to 80% confluence and
resuspended in DMEM. 1 9 105 cells were seeded into
transwell inserts (polycarbonate membrane with 8-lm
pores, 24-well format, Sigma-Aldrich, CLS3422) in
triplicate, and allowed to migrate into the lower cham-
ber with puro-media (10% FBS) for 24 h (MCF-7 sub-
lines) or 48 h (ZR75-1 sublines) under standard cell
culture conditions. Cells were fixed with 3.7%
formaldehyde at room temperature for 15 min and
cells on the upper side of the transwell inserts were
removed before the inserts were stained with crystal
violet. Migrated cells were counted under a light
microscope with a 10x objective. Cell numbers in five
random fields of view were averaged per insert. All
experiments were repeated three times on separate
days.
2.12. Transwell invasion assay
Transwell inserts were coated with 125 lgmL1 matri-
gel overnight under standard cell culture conditions.
Transduced MCF-7 and ZR75-1 sublines were cul-
tured to 80% confluence and resuspended in DMEM.
1 x 105 cells were seeded into transwell inserts in tripli-
cate and allowed to migrate into the lower chamber
with puro-media (10% FBS) for 24 h (MCF-7 subli-
nes) or 48 h (ZR75-1 sublines) under standard cell cul-
ture conditions. Transwell inserts and invaded cell
numbers were processed as described in the migration
assay. All experiments were repeated three times on
separate days.
2.13. RNA-seq
All sublines were seeded in triplicate into 6-well plates
for 24 h (3–4 9 105 to achieve around 70% confluence
the next day). RNA was extracted from the harvested
cells using Trizol. RNA libraries were prepared using
the Illumina TruSeq stranded mRNA library prep kit
(Illumina, 20020594, San Diego, CA, USA). Pooled
libraries were loaded onto a NextSeq 500/550 High Out-
put Flow Cell (single-end, 75 cycles, Illumina, FC-404-
2005) and run on a NextSeq 500 system (Illumina).
FASTQ files were generated by BaseSpace (Illumina)
and mapped to Human GRCh37 Assembly using STAR
[29]. Differential expression was computed in DESeq2.
Genes of ≥ 50 counts, log2(fold change) ≥ |1|, and a false
discovery rate (FDR)-adjusted P-value ≤ 0.05 were
deemed to be differentially expressed.
2.14. Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed
by Enrichr [30] using GO Biological Process 2018.
2.15. Statistical analyses
For cell line experiments, unpaired student t-tests were
performed for two comparisons, and one-way ANOVA
or two-way ANOVA for multiple comparisons, cor-
rected for multiple comparisons using the Dunnett’s or
Sidak’s test, respectively. All results are the mean of
three independent experiments, and error bars represent
the standard deviation (SD) or are otherwise indicated.
All statistical analyses were performed using GRAPHPAD
Prism v. 6.0. An adjusted P-value of < 0.05 was consid-
ered statistically significant.
3. Results
3.1. Differential gene expression in ER+ IDCs
with high vs low Δ40p53
Using RT-qPCR, D40p53 expression levels were mea-
sured in 38 oestrogen-receptor-positive (ER+) and 16
ER- IDCs (Grade 1 and 2) for which gene expression
data has been previously published by our group [24].
To determine genes that are affected by endogenous
Δ40p53, both ER+ and ER- IDCs were classified based
on high or low Δ40p53 expression (as compared to the
median expression level of all IDC cases) (Fig. 1A).
All breast cancer samples were then subjected to
HumanGene1.0 Array (Affymetrix) analysis. In ER+
breast cancer samples, 72 transcripts (59 annotated
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genes, Table 1) were differentially expressed in
tumours expressing high Δ40p53 vs low Δ40p53 (> |
1.5|-fold, P < 0.05, FDR 5%) (Fig. 1B). The same
pattern of differential expression was not observed in
ER- breast cancer cases (Fig. 1C). Thus, the transcrip-
tional effects of Δ40p53 may be ER-dependent. GSEA
revealed GO terms associated with immune responses
mediated by cytokines, which is not surprising given
the fact that the breast cancer specimens contain all
cell types including the tumour cells, stroma, epithe-
lium and the lymphatic cells. Additionally, genes
involved in extracellular matrix organisation, such as
ACTN1 (actinin 1), FBLN1 (fibulin 1) and ITGB2 (in-
tegrin 2), were highlighted by GSEA, indicating
endogenously higher levels of D40p53 are associated
with downregulated cell mobility (Table 2).
3.2. Establishment of Δ40p53 and p53a
knockdown in the ER+ cell lines MCF-7 and
ZR75-1
To further investigate the role of Δ40p53 in ER+
breast cancer, knockdown sublines were established
through shRNA transduction. ER+ MCF-7 and
ZR75-1 cell lines were transduced with shRNA vectors
against p53a (-shp53a), Δ40p53 (-shΔ40p53) and a
nontargeting control (-shNT) (Fig. 2A). The region
targeted by the p53 shRNA (exon 2/3 junction) will
inhibit the expression of all p53 isoforms with the
exception of Δ40p53 (and other N-terminal variants,
i.e. Δ133p53 and Δ160p53, that are transcribed from
the P2 promoter). The region targeted by the Δ40p53
shRNA (intron 2) will result in the inhibition of all
Δ40p53 transcripts (regardless of whether their C ter-
minus is full-length (a) or truncated (b/c)) that are
generated by alternative splicing. Additionally, a
Δ40p53 overexpression model was also established by
transfecting MCF-7 cells with a lentiviral construct
containing the open reading frame of Δ40p53 (MCF-7-
Δ40p53), or an empty lentiviral construct (MCF-7-
LeGO), which served as a control. The D40p53 cDNA
lacks introns; hence, only the full-length D40p53a will
be overexpressed in the MCF-7 cell line.
shp53a was able to inhibit the mRNA expression of
p53a, but not D40p53 in both MCF-7 and ZR75-1 cells
by approximately 80 and 75%, respectively (Fig. 2B,
C). This reduced expression was confirmed at the pro-
tein level with the DO-1 antibody (Fig. 2D,F). Trans-
duction with shD40p53 did not change the mRNA
expression level of p53a but knocked down D40p53
specifically by 65% in MCF-7 cells and 55% in ZR75-1
cells (Fig. 2B,C). These results were confirmed at the
protein level with the KJCA40 antibody (Fig. 2D,F).
Interestingly, in the MCF-7-shp53a subline, the D40p53
mRNA level was increased by 1.4-fold compared to the
nontargeting control (Fig. 2B).
In the overexpression model (MCF-7-Δ40p53),
increased levels of p53a and Δ40p53 were detected
(Fig. 2E), consistent with the stabilising effects of
D40p53 on p53a [14].
Fig. 1. High D40p53 expression is associated with altered gene
expression in 38 ERa+ but not 16 ER- breast tumours. (A) 38 ER+
and 16 ER- breast tumours were divided into high and low D40p53
expression as determined by RT-qPCR using median Δ40p53
expression as the cut-off. Experiments were performed in three
technical replicates. (B) The expression of 28 869 genes was
analysed by gene expression array in the tumour samples.
Hierarchical clustering was performed on 72 transcripts found to
be differentially expressed in high (red branches) vs low (blue
branches) Δ40p53-expressing ERa+ tumours. (C) The 72
differentially expressed transcripts were hierarchically clustered in
ER- breast cancers in high (red) vs low (blue) Δ40p53-expressing
tumours. Similarity in the expression between genes (branches on
left) and between samples (branches on top) was measured using
Euclidean correlation. Distances between clustered branches
represent the average distance. Upregulated expression is
represented by red, downregulated expression is represented by
blue, and equal expression is represented by grey.
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C14orf174 Chromosome 14 open reading frame 174 Up 1.632 0.006
C5orf30 Chromosome 5 open reading frame 30 Up 1.580 0.045
CCDC125 Coiled-coil domain containing 125 Up 1.636 0.014
CYFIP2 Cytoplasmic FMR1 interacting protein 2 Up 1.673 0.043
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 Up 2.340 0.029
EFHC1 EF-hand domain (C-terminal) containing 1 Up 1.528 0.015
FAM174A Family with sequence similarity 174, member A Up 1.515 0.021
GUSBP1 Glucuronidase, beta pseudogene 1 Up 1.609 0.009
GUSBP3 Glucuronidase, beta pseudogene 3 Up 1.773 0.008
HSD17B7 Hydroxysteroid (17-beta) dehydrogenase 7 Up 1.720 0.011
HSD17B7P2 Hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 Up 1.719 0.045
KIF3A Kinesin family member 3A Up 1.511 0.010
KLHDC1 Kelch domain containing 1 Up 1.518 0.030
MCCC2 Methylcrotonoyl-CoA carboxylase 2 (beta) Up 1.618 0.036
MIPOL1 Mirror-image polydactyly 1 Up 1.632 0.021
NUCB2 Nucleobindin 2 Up 1.541 0.021
NUDT12 Nudix (nucleoside diphosphate linked moiety X)-type motif 12 Up 1.592 0.027
SNORA48 Small nucleolar RNA, H/ACA box 48 Up 1.533 0.012
SSBP2 Single-stranded DNA binding protein 2 Up 1.578 0.027
ACTN1 Actinin, alpha 1 Down 1.515 0.016
ARL4C ADP-ribosylation factor-like 4C Down 1.654 0.005
C1R Complement component 1, or subcomponent Down 1.778 0.022
CCR1 Chemokine (C-C motif) receptor 1 Down 1.586 0.041
CD4 Cluster of differentiation 4 Down 1.513 0.034
CERCAM Cerebral endothelial cell adhesion molecule Down 1.525 0.018
CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) Down 2.532 0.013
CHST11 Carbohydrate (chondroitin 4) sulfotransferase 11 Down 1.517 0.019
CNN2 Calponin 2 Down 1.708 0.013
CTSD Cathepsin D Down 1.760 0.039
CYB5R3 Cytochrome b5 reductase 3 Down 1.533 0.004
DPP4 Dipeptidyl-peptidase 4 Down 2.048 0.039
FBLN1 Fibulin 1 Down 1.648 0.043
FLNA Filamin A, alpha Down 1.688 0.004
FPR1 Formyl peptide receptor 1 Down 1.513 0.006
GREM1 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) Down 1.847 0.027
HAS2 Hyaluronan synthase 2 Down 1.763 0.030
ITGB2 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Down 1.564 0.037
KCNJ15 Potassium inwardly-rectifying channel, subfamily J, member 15 Down 1.547 0.032
LAPTM5 Lysosomal protein transmembrane 5 Down 1.612 0.013
LGALS1 Lectin, galactoside-binding, soluble, 1 Down 1.630 0.013
LILRB4 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),
member 4
Down 1.572 0.016
LRP1 Low-density lipoprotein receptor-related protein 1 Down 1.790 0.014
MFGE8 Milk fat globule-EGF factor 8 protein Down 1.732 0.007
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV
collagenase)
Down 1.680 0.038
MYL9 Myosin, light chain 9, regulatory Down 1.539 0.032
PCOLCE Procollagen C-endopeptidase enhancer Down 1.778 0.030
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Down 1.597 0.032
PLAUR Plasminogen activator, urokinase receptor Down 1.554 0.015
PLTP Phospholipid transfer protein Down 1.616 0.027
SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 Down 1.504 0.045
SIRPB1 Signal-regulatory protein beta 1 Down 1.537 0.047
SLC43A3 Solute carrier family 43, member 3 Down 1.579 0.010
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3.3. Δ40p53 knockdown alters the morphology
of ZR75-1 cells
Following successful knockdown of D40p53 or p53a
by shRNA transduction in MCF-7 and ZR75-1 cells
and overexpression of Δ40p53 in MCF-7 cells, we
determined if the long-term knockdown/overexpression
resulted in overt morphological changes. All MCF-7
sublines displayed identical morphology to the paren-
tal MCF-7 cells (Fig. S1A) and were able to form con-
fluent monolayers despite altered D40p53/p53a
expression (Fig. 3A,B,C,E,G). In contrast, ZR75-1
sublines (Fig. 3D,F,H) showed distinct morphological
differences. ZR75-1-shNT and ZR75-1-shp53a cells
(Fig. 3D,H) had identical morphology to the parental
ZR75-1 cells (Fig. S1B), but ZR75-1-shD40p53 cells
(Fig. 3F) aggregated into islands of cells and lost the
ability to form a monolayer.
3.4. Δ40p53 affects proliferation in a cell context-
specific manner
Proliferation was firstly evaluated in all sublines to
determine the role of D40p53 and p53a in cell growth.
In MCF-7 cells, D40p53-overexpression led to an
indicative but not significant reduction in proliferation
compared to the control subline (Fig. 3I), while







SRPX Sushi-repeat-containing protein, X-linked Down 1.817 0.027
STARD3 StAR-related lipid transfer (START) domain containing 3 Down 1.645 0.030
TAGLN Transgelin Down 1.697 0.032
TGM2 Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) Down 1.630 0.008
TIMP1 TIMP metallopeptidase inhibitor 1 Down 1.572 0.013
TMEM45A Transmembrane protein 45A Down 1.867 0.047
TNFRSF21 Tumour necrosis factor receptor superfamily, member 21 Down 1.744 0.004
Table 2. Gene set enrichment analysis of 59 annotated DEGs in ER+ breast cancers.







neutrophil mediated immunity (GO : 0002446) 1.21E-05 0.01 6.25 70.78 CNN2;CYB5R3;ITGB2;PLAUR;
FPR1;CHI3L1;CTSD;MMP9;
SIRPB1
neutrophil activation involved in immune response
(GO : 0002283)
1.13E-05 0.01 6.30 71.78 CNN2;CYB5R3;ITGB2;PLAUR;
FPR1;CHI3L1;CTSD;MMP9;
SIRPB1
negative regulation of cellular component movement
(GO : 0051271)
1.08E-05 0.02 67.80 775.20 ACTN1;CCDC125;FBLN1
neutrophil degranulation (GO : 0043312) 1.06E-05 0.03 6.36 72.80 CNN2;CYB5R3;ITGB2;PLAUR;
FPR1;CHI3L1;CTSD;MMP9;
SIRPB1
cellular response to cytokine stimulus (GO : 0071345) 7.16E-06 0.04 6.68 79.09 CCR1;CD4;ITGB2;FPR1;CHI3L1;
HAS2;TIMP1;MMP9;TNFRSF21
positive regulation of viral entry into host cell
(GO : 0046598)
2.37E-04 0.20 84.75 707.47 CD4;LGALS1
regulation of cysteine-type endopeptidase activity
involved in apoptotic signalling pathway (GO : 2001267)
3.04E-04 0.22 75.33 610.08 PLAUR;MMP9
cytokine-mediated signalling pathway (GO : 0019221) 5.20E-04 0.24 4.28 32.35 CNN2;CCR1;CD4;ITGB2;FPR1;
TIMP1;MMP9;TNFRSF21
extracellular matrix organisation (GO : 0030198) 5.82E-04 0.25 7.37 54.90 GREM1;ITGB2;HAS2;TIMP1;
MMP9
positive regulation of cholesterol efflux (GO : 0010875) 6.54E-04 0.26 52.15 382.43 LRP1;PLTP
Blue genes are downregulated, and red genes are up regulated in breast cancer specimens with high Δ40p53 compared to low Δ40p53.
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proliferation (Fig. 3J). Similarly, knockdown of p53a
in MCF-7 cells led to significant increased prolifera-
tion, consistent with its role as a tumour suppressor
[2]. In comparison, similar growth rates were observed
between ZR75-1-shNT and ZR75-1-shp53a sublines,
but the ZR75-1-shD40p53 subline had a significantly
slower growth rate when compared by the confluence-
based assay (Fig. 3K). However, confluence-based pro-
liferation assays rely on the ability of cells of identical
morphology to form a confluent monolayer. The
unique morphologies amongst the ZR75-1 sublines,
especially the shD40p53 subline, may therefore have
affected confluence-based proliferation assays. There-
fore, a metabolic proliferation assay (Cell Titer Glo
2.0 end-point assay) was used to measure proliferation
in ZR75-1 sublines. The metabolic proliferation assay
indicated that there was no difference in proliferation
between ZR75-1 sublines (Fig. 3L). The above results
showed that D40p53 had cell context-specific effects on
proliferation, decreasing proliferation in MCF-7 cells,
but not ZR75-1 cells, even though both cell lines con-
tain wtp53 and are ER+.
3.5. P53a knockdown enhances cell mobility,
while Δ40p53 overexpression impairs it
Cell mobility was assessed through the scratch wound
assay and the Transwell assay, both of which can be
modified to analyse migration (no matrigel coating) or
invasion (with matrigel coating). MCF-7 cells overex-
pressing D40p53 migrated slower compared to MCF-7-
LeGO cells (empty control vector, Fig. 4A–C). Both
sublines exhibited enlarged cells at the migratory front
and protruding edges stretching towards the cell-free
area, but the wound remained significantly larger in
MCF-7-Δ40p53 cells (Fig. 4B,C). Moreover, MCF-7-
D40p53 cells had greatly impaired invasion capacity
and phenotype compared to MCF-7-LeGO cells
(Fig. 4D–F).
We then sought to assess cell migration/invasion in
the shRNA-transduced MCF-7 sublines. However,
shRNA knockdown of Δ40p53 and p53a altered the
cells’ ability to form a uniform confluent monolayer
overnight (which was achievable in MCF-7-LeGO and
MCF-7-Δ40p53, Fig. 3A,B). Hence, achieving similar
confluence required for wound healing assays was
challenging. To circumvent this issue, transwell assays
were used, which are based on equal seeding density
and do not require similar confluence to be estab-
lished. The number of cells that migrated (Fig. 4G) or
invaded (Fig. 4H) through the membrane of the tran-
swell inserts was not significantly different between
MCF-7-shD40p53 cells and MCF-7-shNT cells. In con-
trast, MCF-7-shp53a cells had acquired significantly
increased cell mobility, indicating p53a as the major
modulator of migration and invasion in MCF-7 cells
(Fig. 4G,H).
ZR75-1 cells had 10-fold less mobility than MCF-7
cells in migration and invasion assays (Fig. 4G–J).
However, consistent with the findings in MCF-7 cells,
ZR75-1-shp53a cells had significantly increased migra-
tory and invasive capability compared to ZR75-1-
shNT cells. ZR75-1-shD40p53 cells had the least cell
mobility, albeit not significantly changed relative to
the shNT control cells (Fig. 4I,J).
Thus, knockdown of p53a resulted in significantly
increased cell migration and invasion in both MCF-7
and ZR75-1 cells, demonstrating a dominant role of
the full-length isoform in these processes. In contrast,
D40p53-overexpression led to reduced cell mobility,
while D40p53 knockdown had no significant effect on
mobility in MCF-7 or ZR75-1 cell lines.
3.6. Molecular profiles support a proliferative,
migratory and invasive phenotype
To evaluate the molecular mechanisms driving differ-
ences in proliferation, migration and invasion between
Fig. 2. Overexpression and knockdown of D40p53 in breast cancer cell lines. (A) The p53 protein includes a transactivation domain (TAD,
blue), a DNA-binding domain (DBD, green) and an oligomerisation domain (OD, purple). The p53 gene has 11 exons. D40p53 lacks part of
the TAD but includes part of intron 2, which shD40p53 targets. Shp53a targets the sequence that spans across exon 2/3, therefore
generating isoform-specific knockdown. Knockdown of p53a and D40p53 was quantitated at the mRNA level in MCF-7 (B) and ZR75-1 (C)
derived cell lines. mRNA expression levels were measured using semiquantitative real-time PCR. All real-time PCR results were normalised
to the housekeeping gene GAPDH, and transduction conditions were compared to the nontargeting shRNA control (shNT). Relative
expression was calculated using 2DDCt method as described [25]. Experiments were repeated three times in three technical replicates.
Results are the mean of three independent experiments, and error bars represent the standard deviation (SD). Significant differences are
indicated with brackets and stars by one-way ANOVA. **P < 0.01, ****P < 0.0001. p53a and D40p53 protein levels were detected by
Western blot in three independent experiments using DO-1 (detecting p53a) and KJCA40 (detecting D40p53) antibodies, respectively. The
protein expression levels of p53a and D40p53 are shown by representative Western blots in the MCF-7 sublines (D) including the pre-
established D40p53-overexpression cells (MCF-7-D40p53 and its control MCF-7-LeGO (E) and the shRNA-transduced sublines, as well as
the transduced ZR75-1 sublines (F).
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Fig. 3. D40p53 can alter cell morphology in ZR75-1 sublines and altered D40p53 and p53a can alter cell proliferation in MCF-7 sublines. The
top panel shows the high-resolution image of D40p53-overexpressing MCF-7 cells (MCF-7-D40p53) (B) and their empty vector control (MCF-
7-LeGO) (A, C, E and G) show stable knockdown of D40p53 and p53a in MCF-7 cells as well as the nontargeting control. (D, F and H) show
stable knockdown of D40p53 and p53a in ZR75-1 cells as well as the nontargeting control. Images were taken by IncuCyte equipped with a
10x objective. Representative images of the sublines parental cells are shown in Fig. S1. Cell proliferation was measured by confluence
using the IncuCyte in D40p53-overexpressing MCF-7 sublines (I) and D40p53/p53a knockdown MCF-7 sublines (J). Cell proliferation of
ZR75-1 sublines was measured by confluence using the IncuCyte (K) and by metabolism using CellTiter Glo (L), normalising to the value of
24 h within each subline. Results are the mean of three independent experiments in triplicate and error bars indicate the standard deviation
(SD). Unpaired t-tests and one-way ANOVA were used to identify significance. ****P < 0.0001.
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D40p53 knockdown/overexpression, p53a knockdown
and control sublines, RNA was extracted from each
subline and subjected to RNA-seq. In both MCF-7
and ZR75-1-derived sublines, knockdown of p53a
altered the expression of less than 1% of the genes
detected by RNA-seq, and the overlap of differentially
expressed genes (DEGs) between the two sublines was
limited to eight genes (Fig. 5A–C, Table S1). Of the
shared DEGs between the p53a-knockdown sublines,
five of the downregulated genes (EIF4A1, SENP3-
EIF4A1, AC016876.2, CD68 and SENP3) are in
proximity of each other on Chr17.p13. Several putative
p53 response elements (RE) have been identified
upstream of CD68 in an in silico analysis [31], indicat-
ing that p53a may control the expression of these
genes via a shared promoter. Three of these overlap-
ping DEGs, EIF4A1, SENP3 and snoRNA SNORA67
(AC016876.2) are involved in translation, indicating
that changes driving increased migration and invasion
in p53a knockdown sublines may be accentuated at
the protein level.
Several of the DEGs support the invasive-migratory
phenotype of the MCF-7 p53a knockdown subline. In
MCF-7-shp53a, increased expression of LRG1 and
HYOU1 (Fig. 5A, Table S1; expression trends con-
firmed by RT-qPCR: Fig. 5I) support increased migra-
tion and invasion of the subline (Fig. 4G,H), as both
genes have been linked to tumorigenicity and cell
migration/invasion [32,33]. These findings also high-
light the tumour suppressing function of p53a. Addi-
tionally, increased HYOU1 [32] and decreased SESN2
[34,35] expression in MCF-7-shp53a (Fig. 5A,
Table S1) support the increased proliferation observed
in the subline (Fig. 3J). SESN2 is a repressor of
mTOR signalling and the reduction in its expression
increases the activity of the pro-proliferative signalling
pathway [34].
In comparison to only nine DEGs in the MCF-7-
shΔ40p53 subline (Fig. 5D, Table S2), 246 differentially
expressed genes were detected in the ZR75-1-shΔ40p53
subline when compared to its’ vector control (Fig. 5E,
Table S2), representing around 3.4% (246/7159) of the
genes detected and offering a possible explanation for
the morphological changes observed in this subline
(Fig. 3F), and highlighting cell line specific effects of
D40p53 on gene expression. GSEA did not yield any sig-
nificant results (Table S3). DEGs in the ZR75-1-
shΔ40p53 subline include downregulation of genes
involved in cell adhesion and extracellular matrix inter-
action (e.g. COL16A1, AMOTL1, ADAMTSL5,
SGCD), as well as downregulation of genes linked to
plasma membrane structure and cytoskeletal organisa-
tion (e.g. BIN3, PICK1, PHACTR1, RHOQ). This dif-
ferential expression provides further support for the
altered morphology observed in these cells. Only four of
the DEGs were common between the two sublines
(Fig. 5F, Table S2). The lack of commonality in DEGs
highlights that Δ40p53 acts in a cell context-specific
manner. Downregulation of UBE2QL1 (log2(fold
change): 1.59; FDR-adj. P-value: 0.0001; Fig. 5D,I,
Table S2), a negative regulator of mTOR pathway
activity, offers a possible explanation for increased pro-
liferation (Fig. 3J), as well as the trend towards
increased migration and invasion observed in the MCF-
7-shΔ40p53 subline (Fig. 4G,H). While the same
changes in cell behaviour (migration and invasion,
Fig. 4I,J) were not observed in the ZR75-1-shΔ40p53
subline, deregulation of additional genes involved in
proliferation, migration and invasion, such as decreased
expression of LRG1, ZMYND8, GNA13, DHX29 and
increased expression of EMILIN2, and RECK may be
counteracting the reduced levels of UBE2QL1 (Fig. 5E,
Table S2) by inhibiting proliferation, migration and
invasion [36–41].
Overall, several of the differentially expressed genes
in Δ40p53 knockdown sublines support the hypothesis
that Δ40p53 acts as a tumour suppressor. Potential
oncogenes upregulated in the Δ40p53 knockdown sub-
lines include EDN1 and CCDC28B in the MCF-7 sub-
line; and LIFR, HOXA11-AS, NACC1, FLT4, AQP3
and FAM129A in ZR75-1-shΔ40p53 cells. Similarly,
decreased expression of tumour suppressor genes was
Fig. 4. D40p53 and p53a can alter cell migration and invasion in MCF-7 and ZR75-1 cells. The metric Relative Wound Density was used to
quantitate cell migration (A) and invasion (D). (B and C) at 72 h after scratch wounds were made in the migration assay. The wound width
of MCF-7-D40p53 cells was larger than that of MCF-7-LeGO cells and the migratory front of MCF-7-D40p53 cells appeared less active than
that of MCF-7-LeGO cells. (E and F) at 72 h after wounds had been made in the invasion assay, MCF-7-D40p53 cells showed impaired
invasion (F) compared to MCF-7-LeGO cells (E). Experiments were repeated three times in triplicate. Representative results and images are
shown. In MCF-7 cells, transwell migration (G) and invasion (H) showed no significant increase in cell mobility when D40p53 was knocked
down but increased cell mobility when p53a was knocked down. In ZR75-1 cells, transwell migration (I) and invasion (J) showed no
significant increase in cell mobility when D40p53 was knocked down but increased cell mobility when p53a was knocked down. Results are
the mean of three independent experiments, and error bars represent the standard deviation of the mean (SD). Experiments were repeated
three times in triplicate. Significant differences are indicated with brackets and stars by one-way ANOVA. *P < 0.05, **P < 0.01,
****P < 0.0001.
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observed when Δ40p53 was knocked down. Downregu-
lated tumour suppressor genes included UBE2QL1 in
both sublines (expression trend confirmed by RT-
qPCR in MCF-7 sublines; Fig. 5I); and SCUBE2,
PPM1L, POLD4, SERPINB9, WWOX, EMSY,
CCAR2, MOB3B, PCAT19, QSOX1, SLX1A, PFDN5,
AMOTL1 and HERC1 in the ZR75-1-shΔ40p53 sub-
line (Fig. 5D,E, Table S2).
Overexpression of Δ40p53 in MCF-7 cells resulted
in the differential expression of 25 genes compared to
MCF-7-LeGO cells (Fig. 5G, Table S4). Several of the
DEGs, such as decreased expression of KLK7 and
LRG1 (expression trends confirmed by RT-qPCR;
Fig. 5I), and increased expression of TNKS1BP1,
PCDH7, and SERPINA5 (expression trends confirmed
by RT-qPCR; Fig. 5I) may be contributing to the
reduction in invasive and migratory properties [33,42–
45] in MCF-7-Δ40p53 cells (Fig. 4A–F, Table S4).
Simultaneously, differential expression of these genes
supports the tumour suppressor role of Δ40p53 in
MCF-7 cells. An observation further strengthened by
opposing observations in MCF-7 Δ40p53 knockdown
cell lines.
Notably, no common DEGs were found between
isoform-specific knockdown in MCF-7 sublines at the
basal level (Fig. 5H), demonstrating loss of D40p53
or p53a alone affected separate gene sets. Together
with the fact that D40p53-overexpression uniquely
induced the expression of 15 genes (Fig. 5H), these
results highlight a p53a-independent function of
D40p53, which has also been reported by others [8].
Contrastingly, 19 DEGs were common to both
ZR75-1-shp53a and ZR75-1-shD40p53 sublines, indi-
cating some similarity in transactivation capacity
between the isoforms, yet even in the ZR75-1 cells,
knockdown of D40p53 affected the expression of 227
genes that were not affected by p53a knockdown
(data not shown). Further, only two genes (DICER
and HLTF) overlapped between MCF-7-shD40p53
and MCF-7-D40p53 (Fig. 5H), indicating that overex-
pression of D40p53 may have different effects on gene
expression than physiological levels of the p53 iso-
form.
4. Discussion
Wtp53 is present in most breast cancers, suggesting
that the canonical tumour suppressing function is com-
promised. We have shown previously that Δ40p53 is
the mostly highly expressed p53 isoform in breast can-
cer, besides the full-length p53a isoform, and that a
high D40p53 : p53a ratio is associated with worse
disease-free survival in breast cancer patients, unveiling
a link between Δ40p53 expression and p53 modulation
endogenously [11]. This lead to the hypothesis that
D40p53 may play a role in breast cancer progression.
Gene expression array analysis identified distinct clus-
tering of differentially expressed genes by higher or
lower D40p53 expression in ER+ cases, but not in ER-
cases (Fig. 1B). DEGs were mostly associated with
immune responses (Table 2), indicating that D40p53
may participate in modulating p53a-mediated immune
responses in ER+ tumours. Indeed, another p53 iso-
form, D133p53, has been shown to be associated with
immunity, interfering with p53a-mediated anti-viral
responses, and inducing inflammation and autoimmu-
nity in mouse models [46]. In contrast, downregulated
genes in tumours with high D40p53 expression were
mostly cytoskeletal components such as ACTN1 and
FBLN1, supporting D40p53’s regulation of cell motil-
ity.
When D40p53 was overexpressed, p53a protein
expression was also enhanced (Fig. 2E), suggesting a
role for D40p53 in stabilising p53a, potentially by
forming a heterotetramer and thus attenuating
HDM2-mediated degradation. This protection phe-
nomenon has been reported in Saos-2 cells by co-
transfection of Δ40p53, p53a and HDM2 [12].
The canonical function of p53a is to monitor DNA
integrity by inducing repair, cell cycle arrest and apop-
tosis. Loss of p53a or mutation of TP53 induces pro-
liferation [2]. Consistently, proliferation was
accelerated when p53a was knocked down in MCF-7
cells. Similarly, Δ40p53 knockdown enhanced prolifer-
ation, though to a lesser extent, while overexpression
of Δ40p53 slightly reduced proliferation in MCF-7
sublines. These findings propose similar roles for
Fig. 5. Differential gene expression in D40p53 and p53a knockdown sublines and the D40p53 overexpression subline. Differential gene
expression in the different isoform knockdown and overexpression sublines relative to their respective control sublines are highlighted
through Volcano plots in which dotted lines represent an false discovery rate (FDR)-adjusted P-value cut-off of 0.05 and a log2(fold change)
cut-off of |1|. Differentially expressed genes are highlighted in red for MCF-7-shp53a vs MCF-7-shNT (A), ZR75-1-shp53a vs ZR75-1-shNT
(B), MCF-7-Δ40p53 vs MCF-7-shNT (D), ZR75-1-shΔ40p53 vs ZR75-1-shNT (E), and MCF-7-Δ40p53 vs MCF-7-LeGO (G). Overlap between
DEGs in the different sublines is minimal (C, F, H), with arrows indicating up/down regulation of the respective genes. Differential
expression of a subset of genes (based on normalised gene counts and relevance) was validated by RT-qPCR (I). Results are the mean of
three independent experiments in triplicate and error bars indicate SD. Unpaired t-tests were used to identify significance and P-values are
shown above the brackets.
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D40p53 and p53a in proliferation suppression in
MCF-7 cells (Fig 3I,J). This proliferation suppression
by D40p53 has been previously demonstrated through
transfection of p53-null cells with Δ40p53 vectors [14].
In ZR75-1 cells, no differences in proliferation were
detected, indicating that these findings are likely cell
context-specific.
p53a regulates cell migration and invasion, mostly
indirectly via other cofactors, but the function of
D40p53 in cell mobility has never been examined
[23]. Epithelia-like breast cancer migration and inva-
sion is generally through a migratory front, which
passively drags the following cells [47]. Therefore,
scratch wound assays were employed. MCF-7 cells
overexpressing D40p53 were less migratory and inva-
sive than MCF-7-LeGO cells (Fig. 4A–F), implying
a role of D40p53 in inhibiting cell mobility. Due to
changes in the ability to form confluent monolayers
and morphological changes in shRNA-transduced
ZR75-1 cells (Fig. 3D,F,H), scratch wound assays
were considered inaccurate. Transwell assays were
therefore performed on shRNA-transduced MCF-7
and ZR75-1 sublines for consistency. Increased
migration and invasion were observed in both cell
lines transduced with p53a-shRNA, indicating that
p53a is a critical safeguard preventing cell mobility.
D40p53-shRNA, on the other hand, mildly impaired
ZR75-1 but not MCF-7 cell mobility (Fig. 4G–J).
The reason could be that there are more extracellu-
lar matrix-associated genes being affected by Δ40p53
in ZR75-1 cells than in MCF-7 cells (discussed
below).
RNA-seq analysis at the basal level showed that
genes associated with increased proliferation potential
and decreased tumour suppression were differentially
expressed following p53a-knockdown (Fig. 5A–C),
supporting the functional assays. Taken together,
these results suggest that loss of p53a in MCF-7
cells enhanced tumorigenicity as expected. Δ40p53
was found to differentially regulate genes linked to
migration and invasion as well as upregulate tumour
suppressor genes and downregulate oncogenes
(Fig. 5D–H). Together with the functional data, this
suggests that at the basal level, the N terminally
truncated isoform Δ40p53 may inhibit migration and
invasion, while also controlling proliferation. D40p53
has been previously reported to retain tumour sup-
pressor function under stress due to the presence of
the second transactivation domain [14]. As such,
D40p53-overexpression at the basal level assimilated
the function of p53a. Whether this is a result of the
stabilising effect Δ40p53 exhibited on p53a is still
unclear at this point. Few of the genes differentially
expressed in D40p53 knockdown and overexpression
sublines are known p53 target genes, which is sup-
ported by the lack of overlap with p53 knockdown
sublines. However, DICER1, which was found to be
downregulated when Δ40p53 was knocked down
(log2(fold change) 1.768 and 4.538 in MCF-7 and
ZR75-1, respectively) as well as when Δ40p53 was
overexpressed in MCF-7 cells (log2(fold change)
1.299) contains a p53RE in its promoter [48].
DICER1 is critical for microRNA (miRNA) matura-
tion, which could post-transcriptionally regulate
mRNA expression [49]. As reviewed by Boominathan
et al. [48], the p53 family mediates a complicated
tumour suppressor miRNA network through
DICER1, controlling tumour suppressor genes such
as PTEN as well as metastasis-associated genes
including ZEB1. The fact that DICER1 is downregu-
lated regardless of Δ40p53 knockdown or overexpres-
sion implies a ratio of Δ40p53 to p53a could be the
key to altering DICER1 and the associated miRNA
network. Additionally, D40p53 expression has been
linked with enhanced stemness in mouse embryos
[18], while as reviewed by Molchadsky et al [50],
p53 is known to promote differentiation and devel-
opment. Hence, altering the levels of the isoforms
may play a role in regulating cell differentiation.
The RNA-seq results showed that the FGFR3
(Fibroblast growth factor receptor 3, promoting dif-
ferentiation) gene was downregulated when D40p53
was knocked down in both MCF-7 and ZR75-1
(Fig. 5F), highlighting the relationship between
D40p53 and stemness/differentiation.
Inconsistent results from MCF-7 and ZR75-1-
derived sublines may result from differences in the
expression of other endogenous regulators. For exam-
ple, HDM2 expression was reported to be higher in
ZR75-1 cells than MCF-7 cells [51] and thus may sup-
press p53a function in this cell line. D40p53 is HDM2-
insensitive and, therefore, may have taken over the
function of p53a to a greater extent in these cells and
provides a possible explanation for greater differential
expression observed in ZR75-1-shD40p53 cells com-
pared to MCF-7-shD40p53 cells (Fig. 5F). Addition-
ally, DEGs associated with cell adhesion and
extracellular matrix organisation in ZR75-1-shD40p53
cells may explain the altered morphology observed in
this subline (Fig. 3F). These DEGs include increased
EMILIN2, RECK and ADMTSL1, as well as
decreased LRG1, COL16A1, QSOX1, KIAA0319,
GNA13, AMOTL1, ADAMTSL5, SGCD and PXDN
(Fig. 5E and Table S2). The discrepancy in induction
of morphological changes may therefore be cell-
dependent.
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This study examined two breast cancer cell lines,
and this is not representative of all breast cancer cases
and subtypes. In particular, our previous studies have
demonstrated that D40p53 expression was found to be
highest in triple negative breast cancers in which TP53
was frequently mutated [3,19]. However, the purpose
of the current study was to define the function of
D40p53 in a wtp53a setting. The role of D40p53 in the
context of mutant p53a needs to be further investi-
gated through other breast cancer cell lines. The cus-
tom shRNAs established as part of this study will be a
very useful tool for this.
5. Conclusion
In summary, examining the role of D40p53 in two
ER+ breast cancer cell lines revealed differential effects
on cell motility in MCF-7 cells but not in ZR75-1
cells. In contrast, p53a, acted to restrain cell motility
in both cell lines, suggesting it plays a more dominant
regulatory role in this context. Together with the
downregulation of putative oncogenes and upregula-
tion of tumour suppressor genes, Δ40p53 stunted pro-
liferation, migration and invasion in MCF-7 cells,
highlighting its cell context-specific function as a
tumour suppressor.
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